Pharma BD Deal Intelligence
Otsuka Pharmaceutical's $886 million all-cash tender offer for Astex Pharmaceuticals at a roughly 48% premium delivered the Dacogen/decitabine franchise plus the PYRAMID fragment-based drug discovery platform. A modest-sized acquisition that traded a rich premium for a durable discovery engine rather than a blockbuster asset.
Otsuka Pharmaceutical acquired Astex Pharmaceuticals for approximately $886 million via an all-cash tender offer at $8.50 per share (a roughly 48% premium), gaining the Dacogen/decitabine franchise and Astex's PYRAMID fragment-based drug discovery platform.
20K US cases/yr · $2.5B Global MDS/AML Market (2013) · $815M Otsuka Acquisition Price
Astex Pharmaceuticals (US entity, previously SuperGen) was acquired by Otsuka for $886M ($8.50/share). The company's lead asset was guadecitabine (SGI-110), a dinucleotide of decitabine designed to resist degradation by cytidine deaminase, potentially improving on existing hypomethylating agents Vidaza and Dacogen for MDS/AML.
The MDS/AML epigenetic therapy market in 2013 was dominated by Celgene's Vidaza (azacitidine) and Eisai's Dacogen (decitabine). Guadecitabine aimed to be a next-generation HMA with better bioavailability. However, the drug ultimately failed its Phase III ASTRAL-1 trial in treatment-naive AML (2020), and the MDS landscape shifted toward combination approaches and venetoclax-based regimens.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Otsuka Pharmaceutical / Astex Pharmaceuticals (this deal) | 2013 | $886M | 48 |
| Otsuka Pharmaceutical / Astex Therapeutics | 2013 | $886M | 48 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2013 deals · Oncology deals